Thank you Mark Cheong, for the opportunity to contribute to this thoughtful piece, led by Dr Billy Rosa, PhD, MBE, APRN, published in The Lancet Infectious Diseases. Tackling a pertinent yet complex clinical care issue through a comprehensive multidisciplinary approach 👇🏾sciencedirect.com/science/articl…

Excited that at #ESCMIDGlobal 2025, SNAP trial results for PSSA and MSSA silo backbone domains will be presented. What's more it's a new format 2 hour session! 3 trials (SNAPx2, CLOCEBA), with expert led & audience discussion. Sat April 12 16:15 - 18:15 Hall 13 Drinks after

Is there epistemic injustice in global AMR research? Here’s what we think cell.com/trends/microbi…

Excited to announce that we randomised our first patient into the #ROADMAPtrial today! First of thousands, answering important questions in prosthetic joint infection. See roadmaptrial.com for more deets. #IDXposts #PJI

SNAP/COLCEBA trial session starting now Steven Tong Joshua Davis Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 Staph aureus causes 1 million deaths per year worldwide. Less than 4.5k randomized in staph aureus bacteremia. Randomized care is better than random care. SNAP platform started on a napkin. #ESCMIDGlobal

Big SNAP trial news at #ESCMIDGlobal - PSSA arm stopped early due to increased AKI with fluclox and lower mortality in penicillin arm (13.8% vs 21.5%) N=281 but results are hard to ignore

The most anticipated RCT in ID 🔥SNAP RCT🔥The largest RCT 2 date in SA bactermia N:1341 Cefazolin Vs ASPs ((flu)cloxacillin) for MSSA bacteremia Cefazolin is non-inferior (90d mortality)& less AKI than ASPs A practice-changer RCT that must change the guidelines #ESCMIDGlobal

#ESCMIDGlobal SNAP Trial Well that really does seem to sign the death warrant for flucloxacillin in MSSA bacteraemia as first line - the power of platform RCTs to answer questions on multiple fronts and change practice. Fantastic global achievement Steven Tong

Cefazolin vs (flu)cloxacillin for MSSA BSI ⭐Non-inferior 90-day mortality ⭐⬇️AKI Also: ⬇️dosing frequency ⬇️phlebitis ?inoculum effect➡️no proven impact on clinical outcome ?CNS penetration➡️myth debunked Is there any reason why (flu)cloxacillin should still be used?

Here's a different perspective. We agree the trial is very important. I dont agree that the fact that I do not consider it to be practice-changing is why we don't get nice things in ID. That's a subject for another day. For now, I have a diff't view of WHY the trial is important.

Amazing summary of the SNAP/CLOCEBA session from yestereday #ESCMIDGlobal. Thanks for posting Bryan White. Nailed all the key points!

Nice summary by Paul Sax on the first of SNAP Trial results recently presented #ESCMIDGlobal2025. Congratulations, Steven Tong Joshua Davis & all participating sites, for answering these questions. Looking forward to its publication & other practice changing answers soon.

(1/5) I would like to highlight one very interesting secondary observation about the impact of non-pharmaceutical interventions, from the data collected in the CENTERSTONE trial ...

🚨 This is Big! New GARDP research shows that people with multidrug-resistant infections in LMICs are not receiving the appropriate antibiotics because of large gaps in access. Improving access and developing new antibiotics must be a priority, 📖 Read the study 👇

Another brilliant episode on #communicable hosted by Dr Erin McCreary & Dr Angela Huttner from practice changing SNAP Trial with Steven Tong & Joshua Davis on the results, which was recently presented at #ESCMIDGlobal2025. ESCMID CMI Communications

We’re setting up a Health Economics Interest Group at ADVANCE-ID and we’re looking for collaborators to join us! ✅ Clinicians, pharmacists, microbiologists ✅ Investigators, research fellows ✅ Any level of experience 📩Interested? Email to Dr. Mo Yin at [email protected]

A monumental achievement for the Malaysian scientific community! Congratulations to Dr Ravigadevi Sambanthamurthi FASc on her election as a Fellow of the Royal Society. This historic recognition marks the first time a Malaysian has been honoured with this distinction since the

SNAP Trial is the little engine that could! Congratulations on passing 4500 participants Steven Tong Joshua Davis

✨We’re excited to share that our Health Economics Interest Group had its very first meet up session yesterday! Thank you to all who joined us as we kicked off a journey into the economics of #InfectiousDiseases & #AMR. Interested get involved? Drop us an email: [email protected]

🚨 BORNEO ANTIMICROBIAL STEWARDSHIP SUMMIT (BAMSS) 2025 📅 26–27 Sept 2025 📍 Auditorium Hall, Centre for Postgraduate Studies, UMS Join healthcare & pharmacy experts to explore the latest in AMS! Early bird ends 29 Aug! 🔗 Register now: bit.ly/BAMSS2025